title: VLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin.
abstract: Acute changes in very low-density lipoprotein (VLDL) triglyceride (TG) and VLDL apolipoprotein (apo) B production were examined in 11 healthy young males in response to insulin delivered either by the peripheral venous route or secreted directly by the pancreas. Steady rates of pancreatic insulin secretion were achieved for 5 h by a programmed intravenous tolbutamide infusion, while euglycemia was maintained with a dextrose infusion. Insulin secretory rate was calculated from peripheral C-peptide levels by deconvolution, and, in a subsequent study, exogenous insulin was infused peripherally to match this pancreatic insulin secretory rate in each subject. Changes in VLDL TG and VLDL apo B production were determined semiquantitatively on each occasion by examining the change in slope of the specific activity (SA) of 3H-labeled triglyceride glycerol ([3H]TGG) and 131I-VLDL apo B vs. time curves, respectively, occurring with acute hyperinsulinemia. Plasma-free fatty acids (FFA), TG, apo B, and VLDL TG/VLDL apo B ratio decreased to a similar extent in both studies after the onset of hyperinsulinemia. VLDL TG production decreased significantly in both the tolbutamide (-47.1 +/- 7.3%, P < 0.002) and the exogenous insulin infusion study (-52.8 +/- 12.4%, P < 0.005). VLDL apo B production also decreased significantly in both studies (-58.9 +/- 7.5%, P = 0.0007 and -52.1 +/- 6.8%, P < 0.006, respectively), and there were no significant differences between studies. Tolbutamide was shown to have no independent effect on VLDL TG or VLDL apo B production in four insulin-deficient diabetic subjects.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of Toronto, Ontario, Canada.
authors.forename: G F
authors.initials: GF
authors.lastname: Lewis
authors.forename: B
authors.initials: B
authors.lastname: Zinman
authors.forename: K D
authors.initials: KD
authors.lastname: Uffelman
authors.forename: L
authors.initials: L
authors.lastname: Szeto
authors.forename: B
authors.initials: B
authors.lastname: Weller
authors.forename: G
authors.initials: G
authors.lastname: Steiner
mesh_terms: D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood; D007275:Injections, Intravenous; D007328:Insulin / Q000008:administration & dosage* / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000096:biosynthesis*; D008297:Male; D011169:Portal Vein; D012016:Reference Values; D013997:Time Factors; D014044:Tolbutamide / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood
chemical_list: D001055:Apolipoproteins B; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D014044:Tolbutamide